BCL10 sirna

BCL10 siRNA (Human)

Cat. Num. AAA8228640

• Gene Names: BCL10; CLAP; mE10; CIPER; IMD37; c-E10; CARMEN
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: BCL10; BCL10 siRNA (Human); CIPER; CLAP; B-cell lymphoma/leukemia 10; B-cell CLL/lymphoma 10; Bcl-10; CARD-containing molecule enhancing NF-kappa-B; CARD-like apoptotic protein; hCLAP; CED-3/ICH-1 prodomain homologous E10-like regulator; Cellular homolog of vCARMEN; cCARMEN; Cellular-E10; c-E10; Mammalian CARD-containing adapter molecule E10; mE10; BCL10 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: BCL10 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 233

• Applicable Applications for BCL10 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human BCL10 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for BCL10 sirna

siRNA to inhibit BCL10 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 4502379
• NCBI GeneID: 8915
• NCBI Accession #: NP_003912.1
• NCBI GenBank Nucleotide #: NM_003921.4
• UniProt Accession #: O95999; Q5VUF1
• Molecular Weight: 26,252 Da
• NCBI Official Full Name: B-cell lymphoma/leukemia 10
• NCBI Official Synonym Full Names: B-cell CLL/lymphoma 10
• NCBI Official Symbol: BCL10
• NCBI Official Synonym Symbols: CLAP; mE10; CIPER; IMD37; c-E10; CARMEN
• NCBI Protein Information: B-cell lymphoma/leukemia 10
• UniProt Protein Name: B-cell lymphoma/leukemia 10
• Protein Family: B-cell lymphoma/leukemia
• UniProt Gene Name: BCL10
• UniProt Synonym Gene Names: CIPER; CLAP; Bcl-10; hCLAP; CIPER; cCARMEN; c-E10; mE10
• UniProt Entry Name: BCL10_HUMAN

NCBI Description

This gene was identified by its translocation in a case of mucosa-associated lymphoid tissue (MALT) lymphoma. The protein encoded by this gene contains a caspase recruitment domain (CARD), and has been shown to induce apoptosis and to activate NF-kappaB. This protein is reported to interact with other CARD domain containing proteins including CARD9, 10, 11 and 14, which are thought to function as upstream regulators in NF-kappaB signaling. This protein is found to form a complex with MALT1, a protein encoded by another gene known to be translocated in MALT lymphoma. MALT1 and this protein are thought to synergize in the activation of NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy. [provided by RefSeq, Jul 2008]

Uniprot Description

Bcl-10: a ubiquitous pro-apoptotic protein that promotes pro-caspase-9 maturation and activation of NF-kappa-B via NIK and IKK. May be an adapter protein between upstream TNFR1-TRADD-RIP complex and the downstream NIK-IKK-IKAP complex. Self-associates via CARD-CARD interactions; forms a tight complex with MALT1. Interacts with other CARD-proteins such as CARD9, CARD10, CARD11 and CARD14. Binds caspase-9 with its C-terminal domain. Interacts with TRAF2 and BIRC2/c-IAP2. Defects in BCL10 are involved in various types of cancer.

Protein type: Tumor suppressor; Apoptosis; Transcription, coactivator/corepressor

Chromosomal Location of Human Ortholog: 1p22

Cellular Component: CBM complex; protein complex; lysosome; immunological synapse; cytosol; lipid raft; T cell receptor complex; cytoplasmic microtubule; perinuclear region of cytoplasm; cytoplasm; plasma membrane; lipopolysaccharide receptor complex; nucleus

Molecular Function: protein C-terminus binding; protein kinase B binding; ubiquitin binding; protein self-association; protease binding; transcription coactivator activity; protein kinase binding; transcription factor binding; NF-kappaB binding; protein binding; enzyme binding; ubiquitin protein ligase binding; kinase activator activity; kinase binding

Biological Process: cell death; response to fungus; positive regulation of transcription, DNA-dependent; positive regulation of caspase activity; B cell apoptosis; T cell receptor signaling pathway; interleukin-6 biosynthetic process; activation of NF-kappaB transcription factor; negative regulation of mature B cell apoptosis; response to molecule of bacterial origin; protein homooligomerization; response to food; adaptive immune response; positive regulation of I-kappaB kinase/NF-kappaB cascade; positive regulation of interleukin-8 biosynthetic process; protein oligomerization; positive regulation of protein ubiquitination; lymphotoxin A biosynthetic process; regulation of T cell receptor signaling pathway; neural tube closure; toll-like receptor signaling pathway; innate immune response; cellular defense response; positive regulation of mast cell cytokine production; positive regulation of T cell activation; immunoglobulin mediated immune response; positive regulation of phosphorylation

Disease: Follicular Lymphoma, Susceptibility To, 1; Mesothelioma, Malignant; Testicular Germ Cell Tumor; Gastric Lymphoma, Primary; Immunodeficiency 37